Amgen psoriatic arthritis drug maintains efficacy after 1 yr -studyReutersJune 11 (Reuters) – A drug being developed by Amgen Inc for psoriatic arthritis demonstrated sustained effectiveness after a year of treatment with no new safety concerns, according to data from a midstage trial. Amgen and partner AstraZeneca Plc had …Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 …MarketWatchBrodalumab Boosts Response in Psoriatic ArthritisMedPage TodayDrug Shows Promise Against Arthritis Common in People with PsoriasisHealthDaySkin and Allergy News Digital Networkall 9 news articles …Read Full Story
Amgen psoriatic arthritis drug maintains efficacy after 1 yr -study - Reuters
Real Estate of Cebu
